1. Pirtobrutinib: A New and Distinctive Treatment Option for B-Cell Malignancies
2. AstraZeneca. Calquence tablet PI, English. Last updated Aug 2022, Accessed March 10, 2024. https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/e2a005a7-65a0-4388-a671-dc887815a938/e2a005a7-65a0-4388-a671-dc887815a938_viewable_rendition__v.pdf.
3. Astrazeneca. Calquence capsule PI, English. Last updated March 2022, Accessed April 1, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210259s009lbl.pdf.
4. Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors
5. AstraZeneca. A study to evaluate relative bioavailability, proton pump inhibitor (PPI) (rabeprazole) effect, food effect and particle size effect of new acalabrutinib tablet in healthy subjects. ClinicalTrials.gov website. Accessed March 10, 2024. https://clinicaltrials.gov/ct2/show/NCT04488016.